Roche Reports Result of Ipatasertib + Tecentriq (atezolizumab) in P-Ib Study for 1L Patients with Advanced Triple-Negative Breast Cancer (TNBC)

 Roche Reports Result of Ipatasertib + Tecentriq (atezolizumab) in P-Ib Study for 1L Patients with Advanced Triple-Negative Breast Cancer (TNBC)

Roche Presents New P-III Data of Tecentriq in Triple-Negative Breast Cancer at ESMO Virtual Congress 2020

Shots:

  • The P-Ib study involves assessing of Ipatasertib + Tecentriq + CT (paclitaxel/nab-paclitaxel) in 26 patients with locally advanced or metastatic TNBC
  • P-Ib study results: ORR 73%; median duration of follow-up 6.1 mos.; Grade ≥3 AEs 54%; all-grade AEs 88%, Presented at AACR 2019
  • Ipatasertib is an oral selective AKT inhibitor targeting three isoforms of AKT further blocking the PI3K/AKT signaling pathway and was developed in collaboration with Genentech & Array BioPharma

Click here to read full press release/ article | Ref: Roche | Image: Chemical Industry Digest

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post